Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma
Status:
Withdrawn
Trial end date:
2020-06-16
Target enrollment:
Participant gender:
Summary
FDA approved drugs to treat patients with relapsed or refractory anaplastic large cell
lymphoma (ALCL) has a median progression free survival of 20 months. Majority of patients
relapse in 2 years. This study will evaluate overall response rate of next generation ALK
inhibitor brigatinib in ALK positive ALCL patients by overcoming mechanisms of resistance to
ALK inhibitors on cancer patients.